Tabassom Mohajershojai
Uppsala, C 75185, Sweden
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Preclinical Validation of [177Lu]Lu-AKIR001, a CD44v6-Targeted Radiotherapeutic Entering First-in-Human Trials.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: July 03, 2025
Enhanced Therapeutic Effects of 177Lu-DOTA-M5A in Combination with Heat Shock Protein 90 Inhibitor Onalespib in Colorectal Cancer Xenografts.
Journal: Cancers
Published: July 21, 2023
p53 stabilisation potentiates [177Lu]Lu-DOTATATE treatment in neuroblastoma xenografts.
Journal: European journal of nuclear medicine and molecular imaging
Published: June 21, 2023
Dual targeting of G9a and DNMTs induces antitumor effects in multiple myeloma.
Journal: Blood advances
Published: May 09, 2023
Photoactive immunoconjugates for targeted photodynamic therapy of cancer.
Journal: Journal of photochemistry and photobiology. B, Biology
Published: December 08, 2022
In Vitro Characterization of 177Lu-DOTA-M5A Anti-Carcinoembryonic Antigen Humanized Antibody and HSP90 Inhibition for Potentiated Radioimmunotherapy of Colorectal Cancer.
Journal: Frontiers in oncology
Published: January 05, 2022
Overcoming Limitations of Cisplatin Therapy by Additional Treatment With the HSP90 Inhibitor Onalespib.
Journal: Frontiers in oncology
Published: February 03, 2020
Showing 1-8 of 8
Last Updated: 09/26/2026